HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senators Request FDA Inquiry Into Lead Discovered In Lipstick Products

This article was originally published in The Rose Sheet

Executive Summary

FDA should "take immediate action" to reduce consumer exposure to lead in lipstick and other cosmetic products, a trio of U.S. Senators assert in a Nov. 19 letter to FDA Commissioner Andrew von Eschenbach, M.D

You may also be interested in...



Sen. Feinstein Plans Cosmetics Bill In Collaboration With Industry, NGOs

Prospects for the developing draft bill are optimistic given the California democratic senator’s reputation for working “effectively across the aisle” and her receptivity to both industry and NGO stakeholders. Janet Nudelman, co-founder of the Campaign for Safe Cosmetics, says the legislation will pick up where negotiations between FDA and industry left off earlier in 2014.

FDA Eyes Industry-Proposed Lead Limit, With Lipstick Report Slated For Fall

FDA is expected to release a report detailing its findings on lead in lipstick this fall, but it remains to be seen whether the agency will heed industry requests to set a maximum limit for the trace contaminant in cosmetic products.

FDA Eyes Industry-Proposed Lead Limit, With Lipstick Report Slated For Fall

FDA is expected to release a report detailing its findings on lead in lipstick this fall, but it remains to be seen whether the agency will heed industry requests to set a maximum limit for the trace contaminant in cosmetic products.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel